COVID-19
Biosimilars
Cataract Therapeutics
DME
Gene Therapy
Workplace
Ptosis
Optic Relief
Imaging
Geographic Atrophy
AMD
Presbyopia
Ocular Surface Disease
Practice Management
Pediatrics
Surgery
Therapeutics
Optometry
Retina
Cataract
Pharmacy
IOL
Dry Eye
Understanding Antibiotic Resistance
Refractive
Cornea
Glaucoma
OCT
Ocular Allergy
Clinical Diagnosis
Technology

Phase III trials begin for steroid compound

March 1, 2007

Article

Tampa-Sirion Therapeutics Inc. has begun enrolling patients in two phase III clinical trials to evaluate difluprednate (ST-601), a steroid compound to treat inflammation after ocular surgery.

Tampa-Sirion Therapeutics Inc. has begun enrolling patients in two phase III clinical trials to evaluate difluprednate (ST-601), a steroid compound to treat inflammation after ocular surgery.

Sirion acquired the drug last year through an exclusive licensing agreement with Senju Pharmaceutical Co. Ltd., Japan. The deal gave Sirion U.S. rights to develop and market a topical ophthalmic emulsion containing difluprednate for the treatment of inflammatory eye diseases.